Whether you believe that ketamine is the most groundbreaking depression treatment to become available this century or that it is a club drug or animal tranquilizer that should be avoided, one thing is certain: ketamine has opened our eyes to a whole new understanding of how the brain works and how to more effectively treat depression, anxiety, PTSD and other psychiatric disorders. Thanks to this new perspective on brain functionality and depression treatment, pharmaceutical companies have taken a new approach to researching and developing drugs for depression treatment. Two promising drugs are on the horizon, and it’s been almost 50 years since a new anti-depressant has hit the market, never mind an effective one!

Janssen Pharmaceuticals received breakthrough therapy status for esketamine—an isomer of ketamine—back in 2016, which has since successfully completed phase I, II and III clinical trials, and is currently seeking official FDA approval. Esketamine is administered intranasally and works well in conjunction with  more traditional antidepressants. However, when administered intranasally, only 25-50% of the medication will reach the brain, resulting in less effective results than traditional IV ketamine.

Allergan also received breakthrough therapy status for its new antidepressant, rapastinel. Rapastinel has completed phases I and II of clinical trials and will moving into phase III shortly. This drug affects the brain the same way that ketamine does, though the chemical structure of the medication is unrelated.

IV ketamine remains the leading route of administration, as 100% of the drug reaches the brain at a precise and calculated rate. It’s also a benefit that IV ketamine is administered in a clinical setting under medical supervision, reducing the risk of abuse, dependency, or that the drug will make it into the wrong hands. Contrary to popular belief, ketamine is not physically addictive—the 6-12 infusions needed to effectively treat depression would not result in physical addiction. Effective in up to 70% of patients, ketamine infusions are highly effective for treating depression and other psychiatric disorders.

Contact Miracle Hills Ketamine

Miracle Hills Ketamine is located in Omaha, NE. We offer ketamine infusion therapy to those in the Omaha area. We treat patients for depression, psychiatric disorders and chronic pain conditions. If you are suffering, ketamine infusions could change your life. Contact us today and speak with a member of our clinical team about the benefits of ketamine for depression, and to find out if you’re a good candidate.